Mithra Pharmaceuticals SA Performance
| MITPFDelisted Stock | USD 6.75 0.00 0.00% |
The company secures a Beta (Market Risk) of 0.0, which conveys not very significant fluctuations relative to the market. the returns on MARKET and Mithra Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Mithra Pharmaceuticals SA has generated negative risk-adjusted returns adding no value to investors with long positions. Despite nearly stable basic indicators, Mithra Pharmaceuticals is not utilizing all of its potentials. The current stock price disturbance, may contribute to mid-run losses for the stockholders. ...more
| Begin Period Cash Flow | 138.7 M | |
| Total Cashflows From Investing Activities | -54.7 M | |
| Free Cash Flow | -95.6 M |
Mithra |
Mithra Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 675.00 in Mithra Pharmaceuticals SA on September 28, 2025 and sell it today you would earn a total of 0.00 from holding Mithra Pharmaceuticals SA or generate 0.0% return on investment over 90 days. Mithra Pharmaceuticals SA is currently producing negative expected returns and takes up 0.0% volatility of returns over 90 trading days. Put another way, 0% of traded pink sheets are less volatile than Mithra, and 99% of all traded equity instruments are likely to generate higher returns over the next 90 trading days. Expected Return |
| Risk |
Mithra Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Mithra Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Mithra Pharmaceuticals SA, and traders can use it to determine the average amount a Mithra Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| MITPF |
Based on monthly moving average Mithra Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Mithra Pharmaceuticals by adding Mithra Pharmaceuticals to a well-diversified portfolio.
Mithra Pharmaceuticals Fundamentals Growth
Mithra Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Mithra Pharmaceuticals, and Mithra Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Mithra Pink Sheet performance.
| Return On Equity | -1.39 | |||
| Return On Asset | -0.11 | |||
| Operating Margin | (3.60) % | |||
| Current Valuation | 425.3 M | |||
| Shares Outstanding | 56.31 M | |||
| Price To Book | 9.76 X | |||
| Price To Sales | 17.08 X | |||
| Revenue | 22.67 M | |||
| EBITDA | (101.58 M) | |||
| Cash And Equivalents | 29.3 M | |||
| Cash Per Share | 0.59 X | |||
| Total Debt | 125.24 M | |||
| Debt To Equity | 9.62 % | |||
| Book Value Per Share | 0.72 X | |||
| Cash Flow From Operations | (74.39 M) | |||
| Earnings Per Share | (2.82) X | |||
| Total Asset | 421.92 M | |||
About Mithra Pharmaceuticals Performance
By analyzing Mithra Pharmaceuticals' fundamental ratios, stakeholders can gain valuable insights into Mithra Pharmaceuticals' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Mithra Pharmaceuticals has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Mithra Pharmaceuticals has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Mithra Pharmaceuticals SA develops, manufactures, and markets complex therapeutics in the areas of contraception, menopause, and hormone-dependent cancers in Europe and internationally. Mithra Pharmaceuticals SA was founded in 1999 and is headquartered in Lige, Belgium. Mithra Pharmaceuticals operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. It employs 300 people.Things to note about Mithra Pharmaceuticals performance evaluation
Checking the ongoing alerts about Mithra Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Mithra Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Mithra Pharmaceuticals is not yet fully synchronised with the market data | |
| Mithra Pharmaceuticals has a very high chance of going through financial distress in the upcoming years | |
| Mithra Pharmaceuticals SA has accumulated 125.24 M in total debt with debt to equity ratio (D/E) of 9.62, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Mithra Pharmaceuticals has a current ratio of 0.78, indicating that it has a negative working capital and may not be able to pay financial obligations in time and when they become due. Debt can assist Mithra Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Mithra Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Mithra Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Mithra to invest in growth at high rates of return. When we think about Mithra Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| The entity reported the revenue of 22.67 M. Net Loss for the year was (116.88 M) with profit before overhead, payroll, taxes, and interest of 6.94 M. | |
| Mithra Pharmaceuticals SA has accumulated about 29.3 M in cash with (74.39 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.59. | |
| Roughly 32.0% of Mithra Pharmaceuticals outstanding shares are owned by corporate insiders |
- Analyzing Mithra Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Mithra Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Mithra Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Mithra Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Mithra Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Mithra Pharmaceuticals' pink sheet. These opinions can provide insight into Mithra Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Mithra Pink Sheet
If you are still planning to invest in Mithra Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Mithra Pharmaceuticals' history and understand the potential risks before investing.
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum |